TY - JOUR
T1 - Androgen Receptor Gene Polymorphisms and Increased Risk of Urologic Measures of Benign Prostatic Hyperplasia
AU - Roberts, Rosebud O.
AU - Bergstralh, Erik J.
AU - Cunningham, Julie M.
AU - Hebbring, Scott J.
AU - Thibodeau, Stephen N.
AU - Lieber, Michael M.
AU - Jacobsen, Steven J.
N1 - Funding Information:
This project was supported by research grants from the Public Health Service, National Institutes of Health (DK60693, DK58859, AR30582 and RR000585).
PY - 2004/2/1
Y1 - 2004/2/1
N2 - The association between androgen receptor gene polymorphisms and benign prostatic hyperplasia was investigated among 510 men randomly selected from Olmsted County, Minnesota. From 1990 through 2000, lower urinary tract symptom severity was assessed by the American Urological Association Symptom Index (AUASI), and peak urinary flow rate, prostate volume, and serum prostate-specific antigen level were measured. Androgen receptor CAG and GGN genotyping was performed. A CAG repeat length of <21 was associated with an enlarged prostate (hazard ratio (HR) = 1.4, 95% confidence interval (Cl): 1.0, 1.9) and a serum prostate-specific antigen level &1.4 ng/ml (HR = 1.5, 95% Cl: 1.1, 2.0). A GGN repeat length of <16 was associated with an AUASI >7 (HR = 1.6, 95% Cl: 1.1, 2.3) and a serum prostate-specific antigen level >1. 4 ng/ml (HR = 1.5, 95% Cl: 1.0, 2.3). Having <21 CAG repeats and <16 GGN repeats compared with having neither was associated with an enlarged prostate (HR = 2.5, 95% Cl: 1.5, 4.2), a serum prostate-specific antigen level >1.4 ng/ml (HR = 2.8, 95% Cl: 1.6, 4.7), a peak flow rate >12 ml/second (HR = 1.9, 95% Cl: 1.1, 3.4), and an AUASI >7 (HR = 1.6, 95% Cl: 1.0, 2.7). Androgen receptor gene polymorphisms may have a potential role in the pathogenesis of benign prostatic hyperplasia.
AB - The association between androgen receptor gene polymorphisms and benign prostatic hyperplasia was investigated among 510 men randomly selected from Olmsted County, Minnesota. From 1990 through 2000, lower urinary tract symptom severity was assessed by the American Urological Association Symptom Index (AUASI), and peak urinary flow rate, prostate volume, and serum prostate-specific antigen level were measured. Androgen receptor CAG and GGN genotyping was performed. A CAG repeat length of <21 was associated with an enlarged prostate (hazard ratio (HR) = 1.4, 95% confidence interval (Cl): 1.0, 1.9) and a serum prostate-specific antigen level &1.4 ng/ml (HR = 1.5, 95% Cl: 1.1, 2.0). A GGN repeat length of <16 was associated with an AUASI >7 (HR = 1.6, 95% Cl: 1.1, 2.3) and a serum prostate-specific antigen level >1. 4 ng/ml (HR = 1.5, 95% Cl: 1.0, 2.3). Having <21 CAG repeats and <16 GGN repeats compared with having neither was associated with an enlarged prostate (HR = 2.5, 95% Cl: 1.5, 4.2), a serum prostate-specific antigen level >1.4 ng/ml (HR = 2.8, 95% Cl: 1.6, 4.7), a peak flow rate >12 ml/second (HR = 1.9, 95% Cl: 1.1, 3.4), and an AUASI >7 (HR = 1.6, 95% Cl: 1.0, 2.7). Androgen receptor gene polymorphisms may have a potential role in the pathogenesis of benign prostatic hyperplasia.
KW - Androgen
KW - Cohort studies
KW - Polymorphism (genetics)
KW - Prostate
KW - Prostatic hyperplasia
KW - Receptors
KW - Risk factors
KW - Signs and symptoms
KW - Urinary retention
UR - http://www.scopus.com/inward/record.url?scp=0942290567&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0942290567&partnerID=8YFLogxK
U2 - 10.1093/aje/kwh042
DO - 10.1093/aje/kwh042
M3 - Article
C2 - 14742287
AN - SCOPUS:0942290567
SN - 0002-9262
VL - 159
SP - 269
EP - 276
JO - American journal of epidemiology
JF - American journal of epidemiology
IS - 3
ER -